Opportunity summary
Score7.0Public score shown from the verified overall while the stale axis breakdown refreshesThis canonical paper page includes Commercialization Proof and Related Resources.
ARXIV:2604.09197 · MEDICAL AI · SUBMITTED 13 APR · 20:23 UTC · FRESHNESS STALE
ARXIV:2604.09197MEDICAL AISUBMITTED 13 APR · 20:23 UTCFRESHNESS STALEFrancesca Fati · Felipe Coutinho · Marika Reinius · Marina Rosanu · Gabriel Funingana · Luigi De Vitis · +22 at arXiv
A multimodal deep learning framework using Vision Transformers can predict chemotherapy response in ovarian cancer from CT scans, acting as a decision-support tool for multidisciplinary teams.
Opportunity summary
Pain A multimodal deep learning framework using Vision Transformers can predict chemotherapy response in ovarian cancer from CT scans, acting as a decision-support tool for multidisciplinary teams.
Evidence 0 refs | 3 sources | 50% coverage
Blocker Evidence unverified
A multimodal deep learning framework using Vision Transformers can predict chemotherapy response in ovarian cancer from CT scans, acting as a decision-support tool for multidisciplinary teams. High-grade serous ovarian carcinoma (HGSOC) is characterized by…
Purpose. High-grade serous ovarian carcinoma (HGSOC) is characterized by pronounced biological and spatial heterogeneity and is frequently diagnosed at an advanced stage.
ScienceToStartup currently rates this 7.0/10 on the public viability pass. In this study, we investigate whether pre-treatment computed tomography (CT) imaging and clinical data can be used to predict CRS as an investigational decision-support…
Medical AI moved forward this cycle; last verified April 2026. Public score 7.0/10. Production flags indicate code availability.
Continue into Read for claims, analysis, references, and neighboring papers.
mobile layout uses overflow-hidden min-w-0 break-wordsOpportunity summary
Score7.0Public score shown from the verified overall while the stale axis breakdown refreshesAnalysis summary
A multimodal deep learning framework using Vision Transformers can predict chemotherapy response in ovarian cancer from CT scans, acting as a decision-support tool for multidisciplinary teams.
Loading BUILD…
Paper Pack
10.48550/arXiv.2604.09197A multimodal deep learning framework using Vision Transformers can predict chemotherapy response in ovarian cancer from CT scans, acting as a decision-support tool for multidisciplinary teams.
Abstract
Purpose. High-grade serous ovarian carcinoma (HGSOC) is characterized by pronounced biological and spatial heterogeneity and is frequently diagnosed at an advanced stage. Neoadjuvant chemotherapy (NACT) followed by delayed primary surgery is commonly employed in patients unsuitable for primary cytoreduction. The Chemotherapy Response Score (CRS) is a validated histopathological biomarker of response to NACT, but it is only available postoperatively. In this study, we investigate whether pre-treatment computed tomography (CT) imaging and clinical data can be used to predict CRS as an investigational decision-support adjunct to inform multidisciplinary team (MDT) discussions regarding expected treatment response. Methods. We proposed a 2.5D multimodal deep learning framework that processes lesion-dense omental slices using a pre-trained Vision Transformer encoder and integrates the resulting visual representations with clinical variables through an intermediate fusion module to predict CRS. Results. Our multimodal model, integrating imaging and clinical data, achieved a ROC-AUC of 0.95 alongside 95% accuracy and 80% precision on the internal test cohort (IEO, n=41 patients). On the external test set (OV04, n=70 patients), it achieved a ROC-AUC of 0.68, alongside 67% accuracy and 75% precision. Conclusion. These preliminary results demonstrate the feasibility of transformer-based deep learning for preoperative prediction of CRS in HGSOC using routine clinical data and CT imaging. As an investigational, pre-treatment decision-support tool, this approach may assist MDT discussions by providing early, non-invasive estimates of treatment response.
Source availability
PDF linkedThe paper record includes a public PDF URL.
Extraction status
Parse run linkedA document parse run is attached to this paper.
Proof status
unverified0 refs; 3 sources; 50% coverage.
What was readable
Derived fallback: Estimated from adjacent evidence; not verified from source.
Viability
Time to MVP
Commercial
Export
Preparing verified analysis
Dimensions overall score 7.0
PROBLEM
A multimodal deep learning framework using Vision Transformers can predict chemotherapy response in ovarian cancer from CT scans, acting as a decision-support tool for multidisciplinary teams. High-grade serous ovarian carcinoma (HGSOC) is characterized by pronounced biological...
METHOD
Purpose. High-grade serous ovarian carcinoma (HGSOC) is characterized by pronounced biological and spatial heterogeneity and is frequently diagnosed at an advanced stage.
RESULT
ScienceToStartup currently rates this 7.0/10 on the public viability pass. In this study, we investigate whether pre-treatment computed tomography (CT) imaging and clinical data can be used to predict CRS as an investigational decision-support adjunct to inform multidisciplinary...
WHY NOW
Medical AI moved forward this cycle; last verified April 2026. Public score 7.0/10. Production flags indicate code availability.
Abstract-backed public claims while anchored extraction refreshes.
A multimodal deep learning framework using Vision Transformers can predict chemotherapy response in ovarian cancer from CT scans, acting as a decision-support tool for multidisciplinary teams. High-grade serous ovarian carcinoma (HGSOC) is characterized by pronounced biological and spatial heterogeneity and is frequently diagnosed at an advanced stage.
Abstract-backed fallback claim; anchored extraction has not materialized a public claim row yet.
partial
Purpose. High-grade serous ovarian carcinoma (HGSOC) is characterized by pronounced biological and spatial heterogeneity and is frequently diagnosed at an advanced stage.
Abstract-backed fallback claim; anchored extraction has not materialized a public claim row yet.
partial
ScienceToStartup currently rates this 7.0/10 on the public viability pass. In this study, we investigate whether pre-treatment computed tomography (CT) imaging and clinical data can be used to predict CRS as an investigational decision-support adjunct to inform multidisciplinary team (MDT) discussions regarding expected treatment response. Code availability is flagged in the production record; the public repository link still needs proof alignment.
Abstract-backed fallback claim; anchored extraction has not materialized a public claim row yet.
partial
Medical AI moved forward this cycle; last verified April 2026. Public score 7.0/10. Production flags indicate code availability.
Abstract-backed fallback claim; anchored extraction has not materialized a public claim row yet.
partial
Paper-native neighborhood for concepts, methods, materials, markets, and competitors. Missing lanes stay labeled instead of disappearing behind commercialization gates.
Concepts
Methods
Materials
Markets
Competitors
A multimodal deep learning framework using Vision Transformers can predict chemotherapy response in ovarian cancer from CT scans, acting as a decision-support tool for multidisciplinary teams.
Segment
Medical AI
Adoption evidence
No public code link in the paper record yet
Commercial read
7.0/10 public viability
Direct
Adjacent
Substitute
Unknown
No indexed public discussion is attached to 2604.09197 yet. That is a visibility signal, not a blank module: the monitor is watching the public channels below.
Hacker News
Not indexed yet
Not indexed yet
Bluesky
Not indexed yet
Preview the source document here, or use the hero PDF action for a new tab.
Reference metadata is not materialized in the public index yet. The source PDF remains the authority; cache refresh is optional.
CITED BY
No citing papers are indexed in the public S2S graph yet. This is an explicit zero-signal state, not a hidden lookup.
Foundation
Extension
Commercially relevant
Conflicting
Owned Distribution
Get the weekly shortlist of commercializable papers, benchmark movers, and proof receipts that matter for product execution.
2/3 checks · 67%
Build Passport
Build passport pending - Proof Lab budget No verified cost estimate / $7.00 cap
status
missing
reason
passport_row_missing
proof status
unverified
cost/budget
No verified cost estimate
confidence low
next verification path
Build brief missing until Build Passport data exists.
Source missing: Build Passport payload.
Experiment plan missing until prototype path is available.
No prototype path attached.
Validation checklist missing until required assets, cost, and regulatory flags are verified.
No checklist artifact is attached to the Build Passport payload.
Derived signals show verified:false until source-backed receipts exist.
Evidence coverage
OpportunityKernel evidence_receipt
0 refs / 3 sources / 50% coverage
stale
Verify missing sources before using this as buyer proof. verified:false
Build readiness
BuildPassport EvidenceState
passport absent
stale
Run Proof Lab or inspect typed missing state. verified:false
Artifact maturity
GitHub and Hugging Face maturity payloads
No public artifact surface observed
stale
Open source artifacts or mark the gap as missing. verified:false
Technical feasibility
partial
Current read
Runnable path is not fully verified.
Evidence
No Build Passport payload attached.
Gaps
Next test
Run minimal reproduction from the Build Passport prototype path.
Market urgency
missing
Current read
Buyer urgency is not verified from source.
Evidence
0 references, 3 sources, 50% evidence coverage.
Gaps
Next test
Collect buyer interview, deployment evidence, or cited demand signal.
Buyer clarity
missing
Current read
No budget owner is verified for this paper.
Evidence
Build tab has no CRM, procurement, or operator source.
Gaps
Next test
Map target operator, economic buyer, and procurement trigger.
Defensibility
missing
Current read
Defensibility signals are missing.
Evidence
No defensibility receipt attached.
Gaps
Next test
Refresh defensibility bars with source receipts.
Integration burden
missing
Current read
No public implementation surface observed.
Evidence
No GitHub or Hugging Face payload attached.
Gaps
Next test
Write integration checklist from prototype path and target workflow.
Capital intensity
missing
Current read
No observed cost estimate is verified.
Evidence
Cost passport has no observed_usd value.
Gaps
Next test
Run cost passport or mark the cost field not applicable.
Regulatory load
missing
Current read
No regulatory classification is attached.
Evidence
Build Passport ledger does not include regulatory flags.
Gaps
Next test
Classify regulatory flags before commercialization planning.
No named scientific founder assigned.
Paper authors are not treated as operators without consent.
People
No named person assigned.
Gaps
Next verification path
Prototype owner missing.
Build Passport does not name an implementer.
People
No named person assigned.
Gaps
Next verification path
Operator workflow not sourced.
No buyer or workflow interview attached.
People
No named person assigned.
Gaps
Next verification path
No GTM owner verified.
No CRM or outreach source attached.
People
No named person assigned.
Gaps
Next verification path
Regulatory need unclassified.
No clinical or regulatory source attached.
People
No named person assigned.
Gaps
Next verification path
ARTIFACTS
No public artifacts yet.
DEFENSIBILITY
Defensibility and confidence evidence pending.
WATCHTOWER
No verified watchtower monitor rows yet.
FORESIGHT
No prediction yet — minted on next Foresight batch.
OPPORTUNITYKERNEL CHANGES SINCE LAST VIEW
No verified OpportunityKernel changes since the last view.
COMPETITIVE LANDSCAPE UPDATES
No verified competitive landscape changes yet.
RELATED PAPER UPDATES
No verified related paper changes yet.
SIGNAL CANVAS HISTORY AND DELTAS
No Signal Canvas history deltas yet.
TIMELINE
Save this paper to start tracking momentum - commits, demos, and score changes appear here.
No tracked events yet.
Score trend will appear after multiple data points.
BUZZ
Buzz trend pending.